Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

• Published in: Vaccine Vol. 29; no. 16; pp. 2874 - 2880
• Main Authors: Stermole, Benjamin M, Grandits, Greg A, Roediger, Mollie P, Clark, Brychan M, Ganesan, Anuradha, Weintrob, Amy C, Crum-Cianflone, Nancy F, Ferguson, Tomas M, Macalino, Grace E, Landrum, Michael L
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 05.04.2011; Elsevier; Elsevier Limited
• Subjects: Adult; adults; Allergy and Immunology; Analysis of Variance; Antibodies, Viral - blood; Antibody Formation; Applied microbiology; Biological and medical sciences; Case-Control Studies; CD4 Lymphocyte Count; Children & youth; cohort studies; Female; Fundamental and applied biological sciences. Psychology; HIV; HIV infections; HIV Infections - immunology; HIV-1 - immunology; Human immunodeficiency virus; Human immunodeficiency virus 1; Human viral diseases; Humans; Immunization; immunoglobulin G; Infectious diseases; linear models; Male; Measles; Measles - prevention & control; Measles-Mumps-Rubella Vaccine - administration & dosage; Medical sciences; Microbiology; Military Personnel; Miscellaneous; MMR Vaccine; Mumps; Mumps - prevention & control; natural history; Public health; Retrospective Studies; Rubella - prevention & control; Seroepidemiologic Studies; seroprevalence; United States; Vaccination; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral diseases; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye; Viral Load; Virology; Young Adult; United States; United States > US; Mumps; Human immunodeficiency virus; Vaccines; Measles; MMR Vaccine; Vaccination; Immunopathology; Rubella; HIV-1 virus; Retroviridae; AIDS; Serology; Vaccine; Immune deficiency; Lentivirus; Infection; Virus; Viral disease
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2011.02.013

Abstract We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls ( p = 0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change −0.04 (±0.18) log10 copies/mL; p = 0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.